Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-07-28

Clinical Trial Update: Dose Reduction and Discontinuation With Anti-Fibrotic Medications

View source ↗

Summary

A completed Boehringer Ingelheim trial update evaluating dose reduction and discontinuation patterns with anti-fibrotic therapy in idiopathic pulmonary fibrosis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • OFEV (Nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Idiopathic Pulmonary Fibrosis | Status: COMPLETED | Results posted: 2025-07-28